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Received November 9, 2010; accepted February 21, 2011AbstractMalignant melanoma of the vagina, a very rare malignancy, has a notoriously aggressive behavior associated with a high risk of local
recurrence and distant metastasis. At present, there are various treatment options for this disease but no standard guideline. We describe a case of
a 54-year-old woman with a locally advanced melanoma of the vagina, who underwent radical surgery, biochemotherapy with interferon-a-2b,
chemotherapy, radiotherapy, and repeat excision of local recurrent lesions and brain metastasis. In conclusion, malignant melanoma of the vagina
has a high risk for local recurrence. Repeated local excision followed by biochemotherapy is a tolerable treatment.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Malignant melanoma of the vagina is a very rare malig-
nancy; fewer than 300 patients have been reported to date. The
aggressive tumor has a poor prognosis, with 5-year survival
rates of 5e25%.1e3 Different surgical treatment options have
been discussed, including radical surgery, exenteration, wide
local excision with pelvic lymphadenectomy, and sentinel
node biopsy. Various adjuvant therapies have been adminis-
tered, including radiotherapy (R/T), chemotherapy (C/T),
immunotherapy, and biochemotherapy (immunotherapy with
C/T). The optimal treatment for vaginal melanoma has been
a subject of debate. We describe a case of malignant mela-
noma of the vagina and review current treatments.* Corresponding author. Dr. Ken-Jen Yu, Department of Obstetrics and Gyne-
cology, KaohsiungVeteransGeneralHospital, 386, Tachung 1st Road, Kaohsiung
813, Taiwan, ROC.
E-mail address: kjyu40@yahoo.com.tw (K.-J. Yu).
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We report a 54-year-old, gravida 5, para 4, and post-
menopausal woman with abnormal vaginal bleeding for 2
months. The patient’s symptoms had worsened in the 2 weeks
before the examination. The patient’s surgical history
included a total abdominal hysterectomy and right salpingo-
oophorectomy because of uterine myoma for about 10 years
ago, without any remarkable familial history of the disease.
The patient visited our gynecologic outpatient department
for help with progressive vaginal bleeding. On gynecologic
examination, there was a 1.0 cm  1.0 cm  0.8-cm raised,
ulcerated, and irregular lesion over the anterior distant third
vaginal wall (Fig. 1). On routine physical examination, there
was no palpable bilateral inguinal lymph node. Biopsy of the
vaginal wall proved the existence of a malignant melanoma in
histopathological studies.
The patient received a major operation including total
vaginectomy, radical vulvectomy, left salpingo-oophorectomy,hinese Medical Association. All rights reserved.
Fig. 1. Gross specimen of total vaginectomy and radical vulvectomy. A dark
brown nodular lesion (short arrow), 1.0 cm  1.0 cm  0.8 cm, is identified in
the vagina. Several irregular dark patches (long arrow) over the adjacent
mucosa.
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lymph node dissection. Rotation of skin flap for perineum
reconstruction had been performed after the radical surgery,
but without neovaginal reconstruction. The tumor was super-
ficial and displayed lentiginous spreading, with a Breslow
depth of 9 mm, ulceration, and cytoplasmic melanin pigmen-
tation. Pathologic reports described a nodular vaginal mela-
noma with clear margins, and all dissected lymph nodes
displayed reactive hyperplasia. The histological diagnosis of
the specimen was confirmed by positive human melanoma
black 45 immunostaining. Based upon the revised tumor size,
lymph node, and metastasis system staging of melanoma of the
American Joint Committee on Cancer produced in 2009, the
patient was staged IIc.4
The patient received postoperative immunotherapy with
interferon-a-2b (IFNa-2b; F. Hoffmann, Switzerland) (15 MIU/
m2, intravenous, 5 d/wk) for 4 weeks. After the initial 4 weeks
of IFNa-2b, the patient accepted the maintaining course of
immunotherapy with IFNa-2b (12 MIU, subcutaneous, 3 times
a week) for 4 months. Unfortunately, the patient received 3
excisions of recurrent vulvar, perineal, and rectal nodules on the
7th, 9th, and 15th months after radical surgery, respectively. AfterFig. 2. The clinical courses of treatment, from 2008 to 2010.*Operation: total vagin
lymph node dissection þ bilateral inguinal lymph node dissection þ rotation fla
***Operation: left F-T-P craniotomy þ removal of brain tumor Radiotherapy: 610
4500 cGy, 25 fractions over whole pelvic and bilateral inguinal nodal regions.the first and second excisions, she accepted C/T with Dacarba-
zine, dimethyl-triazeno imidazole-carboxamide (Hospira,
Australia), 850 mg/m2 every month for 6 courses. At last exci-
sion, she was given immunotherapy with IFNa-2b (12 MIU,
subcutaneous, 5 days a week) and R/T 6100 cGy, 33 fractions
over the perineum, for local control.
However, one month after the third excision, the patient
suffered from slurred speech/facial palsy and complained of
recurring headache, which began approximately two months
before the operation. Magnetic resonance imaging of the brain
revealed an intra-axial mass lesion about 3.0 cm  2.6 cm 
2.8 cm at the left temporo-parietal junction. Metastatic
melanoma was determined to be the most likely diagnosis. The
patient underwent craniotomy and resection of the brain
lesion. Histological examination proved that the patient had
metastatic melanoma. After resection of the brain tumor, the
patient accepted immunotherapy with IFN (12 MIU, subcu-
taneous, 5 days a week) and R/T 3000 cGy, 10 fractions over
the whole brain, and 4500 cGy, 25 fractions over the whole
pelvic and bilateral inguinal nodal regions. Later, the patient
underwent repeated IFN and dimethyl-triazeno imidazole-
carboxamide treatments, and resection of residual brain
metastatic tumor. The patient is still alive, more than 30
months, after initial diagnosis (Fig. 2).
3. Discussion
Malignant melanoma of the vagina is very rare, accounting
for 0.3e0.8% of all melanomas in women, 2e5% of female
genital-tract melanomas, and less than 3% of vaginal tumors.1
The tumor typically presents in the sixth and seventh decades
of life and occurs more commonly in the lower third of the
vagina and mostly on the anterior vaginal wall.1,2 The
appearance of tumors is almost always pigmented; only
10e23% are amelanotic.5 The most common symptom is
abnormal vaginal bleeding.2
This disease is associated with a high risk of local recur-
rence, distant metastasis, and poor clinical outcome. A retro-
spective review of vaginal melanoma disease by Michael et al
revealed that the median survival of 37 cases in Stage I was
19.1 months.2 Studies by Michael et al and Reid et al have
shown that the tumor size and nodal status are significant
prognostic factors, whereas tumor thickness is a weak predictorectomy þ radical vulvectomy þ left salpingo-oophorectomy þ bilateral pelvic
p **Operation: left F-T-P craniotomy þ removal of brain metastatic tumor
0 cGy, 33 fractions over perineum; 3000 cGy, 10 fractions over whole brain;
Table 1
The summary of two clinical trials of Peg-IFN treatment on malignant melanoma
Study No. of
patients
TNM stage IFN regimens Arms: No. of
patients
Outcome
Eggermont
(EORTC 18991)13
1256 TanyN þ M0
Stage III
Peg-IFN 6 mg/kg/wk for 8 wk (sc)
then 3 mg/kg/wk for 5 y (sc)
Peg-IFN: 627 4-year RFS rate
Peg-IFN: 45.6%
OBS: 38.9%
p ¼ 0.02
OBS: 629
Bottomley14 1256 TanyN þ M0
Stage III
Peg-IFN 6 mg/kg/wk for 8 wk (sc)
then 3 mg/kg/wk for 5 y (sc)
Peg-IFN: 627 Global HRQUL
Peg-IFN is significantly lower than OBS
p < 0.004
OBS: 629
HRQUL ¼ Health-related quality of life; IFN ¼ interferon; OBS ¼ Observation; Peg-IFN ¼ pegylated IFNa-2b; RFS ¼ recurrence free survival; TNM ¼ tumor
size, lymph node, and metastasis.
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data regarding therapeutic options. Several treatment options
are administered but none of them are considered to be
a standard approach. Surgical resection is considered the first
treatment of choice with survival benefit.2,5 Different surgical
methods such as wide local excision, radical surgery (total
vaginectomy with or without vulvectomy), and pelvic extent-
eration have been described. However, research has continued
to demonstrate that there is actually no difference in survival
between patients who have radical surgical procedures and
those who have more conservative surgical procedures.3,5,7
Some authors suggest that radical surgery should be per-
formed due to the more aggressive behavior of vagina mela-
noma.8,9 After surgery, patients with a high risk of recurrence
(including regional lymph node involvement or thicker primary
tumors, i.e. American Joint Committee on Cancer Stage IIb/IIc/
III) should be considered for adjuvant therapy.
Immunotherapy with IFN has been demonstrated to reduce
recurrence rates and offer a survival advantage.10,11 The Food
and Drug Administration approved of high-dose IFN based on
the results of a randomized Phase III trial (E1684).10 IFN is the
only drug approved by the Food and Drug Administration for
adjuvant therapy in patients with malignant melanoma who are
free of disease but at a high risk of systemic recurrence. An
updated individual patient meta-analysis of 14 trials reported
statistically significant improvement in both disease-free survival
and overall survival in patients who received IFN.12 Pegylated
IFNa-2b (Peg-IFN), a derivative of recombinant IFN, does not
compromise its effect and can be conveniently given once aweek
because of longer half-life. Peg-IFN has reduced toxicity, and
toxicity does not seem to increase with longer duration of treat-
ment.We reviewed two trials of Peg-IFN treatment onmalignant
melanoma, which are summarized in Table 1.13,14 In the future,
IL-2 and vaccine therapymay be the other options; however, they
do not seem to improve the overall survival rate of patients with
malignant melanoma.15
The role of cytotoxic C/T in vaginal melanoma has not been
completely defined because of the small number of cases.
Dacarbazine has been considered the standard of treatment for
metastatic or recurrent melanoma since 1972. Other useful
antineoplasm agents include temozolomide, platinum analogs,
nitrosoureas, and taxanes. The response rate of these single
agents is 11e22%, with median overall survival of 5.6e11
months. Combination C/T that is most commonly usedfor melanoma includes Dartmouth regimen (Dacarbazine/
Carmustine/Cisplatin/Tamoxifen) and CVD regimen (Cisplatin/
Vinblastine/Dacarbazine), which are proved to increase objec-
tive response rate but have no overall survival benefit.16 Based
upon the above observations, it may be possible to develop
combination C/T regimens that improve overall survival in the
future.
Some authors have considered biochemotherapy, a combi-
nation of C/T and immunotherapy, as a possible valid option
after surgery to improve patient survival. Biochemotherapy is
associated with higher response rates than other C/T regimens
or immunotherapy for treatment of metastatic melanoma, but
offers no survival benefit.17
The role of elective lymph node dissection remains contro-
versial. Instead, sentinel lymph node biopsy (SLNB), which
provides important prognostic and staging data with minimal
morbidity, has recently gained popularity.18 Routine lymph
node dissection is not recommended because the morbidity
associated with lymphadenectomy is high and prophylactic
lymphadenectomy has not been shown to improve survival in
vaginal melanoma.4 Overall survival is significantly higher in
patients who undergo SLNB and immediate lymphadenectomy
compared with those who have lymphadenectomy only after
having clinically detectable disease.19 SLNB should be per-
formed on most patients who have melanomas with a Breslow
depth0.76 mm.18 However, in our case, the lymph nodes were
dissected to provide for a complete staging of the tumor.
R/T also for local control has been mostly offered in the
following two conditions, surgically non-resectable disease or
as an adjuvant therapy in case of pathologically positive
margins or positive lymphadenopathy.2,5
In conclusion, primary malignant melanoma of the vagina
has poor prognosis at any stage, with high risk of local
recurrence and distant metastasis. Surgical intervention seems
to improve survival. After operation, adjuvant therapy should
be considered for patients with a high-risk recurrence. In our
case, repeated local excision followed by biochemotherapy/
chemotherapy/radiation therapy was a tolerable treatment.References
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